MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10072-022-06403-2

Медицинская библиотека · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022

Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.

Le Goff Laure, Seferian Andreea, Phelep Aurelie, Rippert Pascal, Mathieu Marie-Laure, Cances Claude, de Lattre Capucine, Durigneux Julien, Gousse Gaelle, Vincent-Genod Dominique, Ribault Shams, Gomez Garcia de la Banda Marta, Quijano-Roy Susana, Sarret Catherine, Servais Laurent, Vuillerot Carole

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To evaluate sensitivity to change and discriminant validity of the 20-item Motor Function Measure (MFM-20) in 2-7-year-old patients with spinal muscular atrophy types 1 (SMA1) or 2 (SMA2) treated with nusinersen.

METHODS

Children aged 2 to 7 years old with SMA1 or SMA2 treated with nusinersen were assessed at least three times using the MFM-20 over an average follow-up time of 17 months. Evolution of 4-month-standardized MFM-20 scores was calculated for each MFM-20 domain (D1 standing and transfers, D2 axial and proximal, D3 distal) and for the total score (TS).

RESULTS

Included in the study were 22 SMA1 subjects and 19 SMA2 subjects. Baseline MFM scores were significantly lower in patients with SMA1 than SMA2 (TS 29.5% vs. 48.3%, D1 4.5% vs. 10.6%, D2 43.6% vs. 72.6%, D3 51.2% vs. 75.0%). When considering the mean change during nusinersen treatment, standardized over a 4-month period, TS was improved for both SMA1 (+ 4.1%, SRM 1.5) and SMA2 (+ 2.8%, SRM 0.89) patients. For SMA1 patients, considerable changes were observed in D2 (+ 6.2%, SRM 0.89) and D3 (+ 6.0%, SRM 0.72), whereas the change in D1 was small (+ 0.5%, SRM 0.44). In SMA2 2 subjects, D3 was improved to a larger extent (+ 4.2%, SRM 0.53) than D1 (+ 1.8% SRM 0.63) or D2 (+ 3.2%, SRM 0.69).

CONCLUSION

Our results validate use of MFM-20 to monitor function of young SMA1 and SMA2 subjects treated with nusinersen. Significant motor function improvements following treatment were observed in both SMA1 and SMA2 patients.

Для цитирования: Le Goff Laure, Seferian Andreea, Phelep Aurelie, Rippert Pascal, Mathieu Marie-Laure, Cances Claude, de Lattre Capucine, Durigneux Julien, Gousse Gaelle, Vincent-Genod Dominique, Ribault Shams, Gomez Garcia de la Banda Marta, Quijano-Roy Susana, Sarret Catherine, Servais Laurent, Vuillerot Carole. Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2022. DOI: 10.1007/s10072-022-06403-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.